Aignostics

Executive Summary

Aignostics is a Berlin-based AI startup transforming pathology data into actionable insights for biopharma companies. Their platform applies machine learning to complex biomedical data to accelerate drug development from target identification through translational research to clinical trials and companion diagnostics. Founded in 2018, the company addresses a critical need for precision medicine in oncology, where traditional pathology methods are time-consuming and subjective. By leveraging AI, Aignostics enables faster, more accurate analysis of tissue samples, potentially reducing development timelines and costs. The company has likely raised early-stage funding and is building partnerships with pharma and diagnostic companies. With the growing adoption of digital pathology and AI in healthcare, Aignostics is well-positioned to capture market share. The team's expertise in both AI and pathology gives them a competitive edge. However, challenges include regulatory hurdles, data privacy, and competition from other AI pathology startups. Overall, Aignostics represents a promising opportunity in the intersection of AI and oncology precision medicine.

Upcoming Catalysts (preview)

• Q3 2026Series B Funding Round75% success
• Q4 2026Major Pharma Partnership for AI-Powered Companion Diagnostics60% success
• Q2 2027FDA Clearance for First AI Pathology Product50% success